AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32860031 — intervention group
Group type: EXPERIMENTAL
Intervention: Vupanorsen 20 mg QW
Number of subjects: 105
Study 32860031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 33837592 — intervention group
Group type: EXPERIMENTAL
Intervention: LL-BFR training (9 sessions of low-load blood flow restricted exercise)
Number of subjects: 18
Study 33837592 — intervention group
Group type: COMPARATOR
Intervention: SHAM-BFR training (equal training with sham vascular occlusion)
Number of subjects: 18
Study 33837592 — intervention group
Group type: COMPARATOR
Intervention: Both LL-BFR and SHAM-BFR training
Number of subjects: 18
Study 33837592 — intervention group
Group type: COMPARATOR
Intervention: Control group (for muscle biopsy analysis)
Number of subjects: 18
Study 32152347 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS) with anode over left-dorsolateral prefrontal cortex
Number of subjects: 60
Study 32152347 — intervention group
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Number of subjects: 60
Study 34561058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education program for biologically male participants
Number of subjects: 75
Study 34561058 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle education program for biologically female participants
Number of subjects: 75
Study 34561058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lifestyle education)
Number of subjects: 75
Study 32632842 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding initiation
Number of subjects: 370
Study 32632842 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) percentile
Number of subjects: 370
Study 32632842 — intervention group
Group type: EXPERIMENTAL
Intervention: Birthweight
Number of subjects: 370
Study 32632842 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI percentile comparison based on caregiver's birthplace
Number of subjects: 370
Study 32632842 — intervention group
Group type: COMPARATOR
Intervention: Breastfeeding duration
Number of subjects: 370
Study 32632842 — intervention group
Group type: COMPARATOR
Intervention: Bottle feeding duration
Number of subjects: 370
Study 32632842 — intervention group
Group type: COMPARATOR
Intervention: Age when solid foods were introduced
Number of subjects: 370
Study 35538056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 115
Study 35538056 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 115
Study 35538056 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise + Diet
Number of subjects: 115
Study 35538056 — intervention group
Group type: COMPARATOR
Intervention: No Intervention
Number of subjects: 115
Study 35076327 — intervention group
Group type: EXPERIMENTAL
Intervention: Local oestrogen (oestriol) therapy
Number of subjects: 67
Study 35076327 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 67
Study 32975783 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration profiling (constantly declining UF rate)
Number of subjects: 34
Study 32975783 — intervention group
Group type: COMPARATOR
Intervention: Conventional ultrafiltration
Number of subjects: 34
Study 36011468 — intervention group
Group type: EXPERIMENTAL
Intervention: Veggie Van (VV) mobile market model intervention for one year
Number of subjects: 0
Study 36011468 — intervention group
Group type: COMPARATOR
Intervention: Control sites hosting planning events
Number of subjects: 0
Study 35549760 — intervention group
Group type: EXPERIMENTAL
Intervention: CBE stent (BARD®LIFESTREAM™)
Number of subjects: 106
Study 35549760 — intervention group
Group type: COMPARATOR
Intervention: CSE stent (GORE® VIABAHN™)
Number of subjects: 106
Study 33247572 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8mg
Number of subjects: 40
Study 33247572 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac tromethamine 20mg
Number of subjects: 40
Study 33099947 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative neo‐adjuvant chemotherapy+surgery+postoperative radiotherapy
Number of subjects: 143
Study 33099947 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery+postoperative radiotherapy)
Number of subjects: 143
Study 33099947 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐182 predictive value
Number of subjects: 143
Study 33107363 — intervention group
Group type: EXPERIMENTAL
Intervention: Transoral robotic surgery (TORS)
Number of subjects: 250
Study 32760092 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical honey
Number of subjects: 29
Study 32760092 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 35426318 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA)
Number of subjects: 128
Study 35426318 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 128
Study 35426318 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive‐Behavioral Transdiagnostic Therapy (TD‐CBT)
Number of subjects: 128
Study 35426318 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 128
Study 32607811 — intervention group
Group type: EXPERIMENTAL
Intervention: High ADMA levels
Number of subjects: 115
Study 32807162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde (27 μg/mL)
Number of subjects: 33
Study 32807162 — intervention group
Group type: COMPARATOR
Intervention: 0.5% sodium hypochlorite
Number of subjects: 33
Study 36423855 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home-based progressive resistance training (RT) for 22 weeks
Number of subjects: 31
Study 36423855 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTL)
Number of subjects: 31
Study 36423855 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised home-based progressive resistance training (RT)
Number of subjects: 31
Study 33226605 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 32
Study 33226605 — intervention group
Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 32
Study 32996722 — intervention group
Group type: EXPERIMENTAL
Intervention: anodal tDCS (7, 13, and 20 min duration)
Number of subjects: 15
Study 32996722 — intervention group
Group type: EXPERIMENTAL
Intervention: hf‐tRNS (1mA for 7, 13, and 20 min duration)
Number of subjects: 15
Study 32996722 — intervention group
Group type: EXPERIMENTAL
Intervention: hf‐tRNS (1mA for 13 min duration)
Number of subjects: 15
Study 32996722 — intervention group
Group type: EXPERIMENTAL
Intervention: hf‐tRNS (1mA for 20 min duration)
Number of subjects: 15
Study 36493503 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 211
Study 36493503 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 211
Study 33845098 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich drink
Number of subjects: 82
Study 33845098 — intervention group
Group type: COMPARATOR
Intervention: Control (no intake after midnight)
Number of subjects: 82
Study 32957971 — intervention group
Group type: EXPERIMENTAL
Intervention: PACE Steps to Success intervention
Number of subjects: 0
Study 32957971 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 0
Study 35429285 — intervention group
Group type: EXPERIMENTAL
Intervention: 101BHG‐D01 nasal spray (40 µg to 960 µg)
Number of subjects: 0
Study 35429285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32949027 — intervention group
Group type: EXPERIMENTAL
Intervention: VL20 (20% repetition velocity loss)
Number of subjects: 22
Study 32949027 — intervention group
Group type: EXPERIMENTAL
Intervention: VL40 (40% repetition velocity loss)
Number of subjects: 22
Study 32949027 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (VL20 and VL40)
Number of subjects: 22
Study 32779140 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in choice eConsult program
Number of subjects: 305915
Study 32779140 — intervention group
Group type: COMPARATOR
Intervention: Traditional referrals
Number of subjects: 305915
Study 36055678 — intervention group
Group type: EXPERIMENTAL
Intervention: TOLAC (Trial of Labor After Cesarean)
Number of subjects: 620
Study 36055678 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalopelvic score
Number of subjects: 620
Study 36055678 — intervention group
Group type: EXPERIMENTAL
Intervention: Full engagement in the pelvis
Number of subjects: 620
Study 36055678 — intervention group
Group type: EXPERIMENTAL
Intervention: Bishop cervical maturity score
Number of subjects: 620
Study 33141110 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia (oxycodone)
Number of subjects: 164
Study 33141110 — intervention group
Group type: COMPARATOR
Intervention: Nurse-administered oral oxycodone
Number of subjects: 164
Study 34848133 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat 2.5 mg three times daily
Number of subjects: 396
Study 34848133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 396
Study 33180322 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP CML-CP recommended therapy
Number of subjects: 630
Study 33180322 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP CML-CP model
Number of subjects: 630
Study 33180322 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP CML-CP recommendation
Number of subjects: 630
Study 33180322 — intervention group
Group type: EXPERIMENTAL
Intervention: Backward multivariate analysis
Number of subjects: 630
Study 34279411 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing tea tree oil (TTO) and ethanolic extract of propolis (EEP)
Number of subjects: 50
Study 34279411 — intervention group
Group type: COMPARATOR
Intervention: Toothpaste without tea tree oil (TTO) and ethanolic extract of propolis (EEP)
Number of subjects: 50
Study 32172954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal ropivacaine
Number of subjects: 40
Study 32172954 — intervention group
Group type: COMPARATOR
Intervention: Saline (Placebo)
Number of subjects: 40
Study 35129040 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg LN18178
Number of subjects: 120
Study 35129040 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg LN18178
Number of subjects: 120
Study 35129040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 34332640 — intervention group
Group type: EXPERIMENTAL
Intervention: Training intervention for emergency medical operators
Number of subjects: 32
Study 34332640 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 32
Study 33763399 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture containing Saccharomyces boulardii, Lactobacillus acidophilus, Lactobacillus paracasei, Bifidobacterium lactis Bl-04, and Bifidobacterium lactis Bi-07 (Bactiol duo®)
Number of subjects: 120
Study 33763399 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture
Number of subjects: 120
Study 33763399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 33763399 — intervention group
Group type: COMPARATOR
Intervention: Saccharomyces boulardii
Number of subjects: 120
Study 36060828 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISm group
Number of subjects: 343
Study 36060828 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD group
Number of subjects: 343
Study 32158015 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep infiltrating endometriosis (group 2)
Number of subjects: 40
Study 32158015 — intervention group
Group type: COMPARATOR
Intervention: Control group (eutopic endometrium of adenomyosis- and endometriosis-free women)
Number of subjects: 40
Study 32158015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 32158015 — intervention group
Group type: EXPERIMENTAL
Intervention: Atypical ovarian endometriosis
Number of subjects: 40
Study 32158015 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study 32158015 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep infiltrating endometriosis and lymph node endometriosis
Number of subjects: 40
Study 32158015 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometriotic neuropathy
Number of subjects: 40
Study 32506943 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiphospholipid antibody IgG positivity in patients with dysglycaemia
Number of subjects: 805
Study 32506943 — intervention group
Group type: COMPARATOR
Intervention: Normoglycaemic participants
Number of subjects: 805
Study 35595254 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly factor VIII prophylaxis (10 U/kg)
Number of subjects: 33
Study 35595254 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly factor VIII prophylaxis (10 U/kg)
Number of subjects: 33
Study 35595254 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly factor VIII prophylaxis
Number of subjects: 33
Study 35595254 — intervention group
Group type: COMPARATOR
Intervention: Thrice weekly factor VIII prophylaxis
Number of subjects: 33
Study 33079180 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab (700 mg subcutaneously, repeated after 7 days in 17 of 23 patients)
Number of subjects: 23
Study 33079180 — intervention group
Group type: EXPERIMENTAL
Intervention: Leronlimab
Number of subjects: 23
Study 34902549 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAPT plus treatment as usual (TAU)
Number of subjects: 79
Study 34902549 — intervention group
Group type: COMPARATOR
Intervention: TAU only
Number of subjects: 79
Study 34902549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ADAPT+TAU and TAU)
Number of subjects: 79
Study 33411586 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line daratumumab (DRd)
Number of subjects: 0
Study 33411586 — intervention group
Group type: COMPARATOR
Intervention: Second-line daratumumab (Rd)
Number of subjects: 0
Study 35862871 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib 450 mg once daily plus binimetinib 45 mg twice daily
Number of subjects: 577
Study 35862871 — intervention group
Group type: COMPARATOR
Intervention: Vemurafenib 960 mg twice daily
Number of subjects: 577
Study 35862871 — intervention group
Group type: COMPARATOR
Intervention: Encorafenib 300 mg once daily
Number of subjects: 577
Study 34605584 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended sales hours from 3 pm to 4 pm on Saturdays starting in September 2020, December 2020, or March 2021.
Number of subjects: 228
Study 34605584 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extended sales hours).
Number of subjects: 228
Study 32389020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PNI
Number of subjects: 99
Study 32389020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low KPS score
Number of subjects: 99
Study 32389020 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor tumor differentiation
Number of subjects: 99
Study 32389020 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain metastasis
Number of subjects: 99
Study 32389020 — intervention group
Group type: EXPERIMENTAL
Intervention: High NLR
Number of subjects: 99
Study 35084092 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF) using titanium miniplates and screws
Number of subjects: 20
Study 35084092 — intervention group
Group type: COMPARATOR
Intervention: Closed method with inter-maxillary fixation
Number of subjects: 20
Study 33522396 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat (LF) meal, 15 g of fat
Number of subjects: 12
Study 33522396 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate fat (MF) meal, 30 g of fat
Number of subjects: 12
Study 33522396 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (HF) meal, 60 g of fat
Number of subjects: 12
Study 33522396 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat (HF) meal administered twice for reproducibility
Number of subjects: 12
Study 34811567 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipotent adult progenitor cells (900 million cells)
Number of subjects: 30
Study 34811567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 33201281 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching through drawing
Number of subjects: 80
Study 33201281 — intervention group
Group type: COMPARATOR
Intervention: Standard teaching
Number of subjects: 80
Study 35135619 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTION intervention (Acceptance and Commitment Therapy) plus treatment as usual
Number of subjects: 80
Study 35135619 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 80
Study 33536677 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM) diagnosis using WHO 2013 criteria
Number of subjects: 612
Study 33536677 — intervention group
Group type: COMPARATOR
Intervention: Being overweight or obese
Number of subjects: 612
Study 33536677 — intervention group
Group type: COMPARATOR
Intervention: Past history of pre‐term delivery
Number of subjects: 612
Study 33536677 — intervention group
Group type: COMPARATOR
Intervention: Past history of stillbirths
Number of subjects: 612
Study 33536677 — intervention group
Group type: COMPARATOR
Intervention: History of macrosmia
Number of subjects: 612
Study 33536677 — intervention group
Group type: COMPARATOR
Intervention: Alcohol consumption
Number of subjects: 612
Study 33536677 — intervention group
Group type: COMPARATOR
Intervention: Having a first degree relative with diabetes mellitus
Number of subjects: 612
Study 35140139 — intervention group
Group type: EXPERIMENTAL
Intervention: Gender socialisation (GS) intervention
Number of subjects: 0
Study 35140139 — intervention group
Group type: EXPERIMENTAL
Intervention: GS and financial literacy intervention
Number of subjects: 0
Study 35140139 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 32022581 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 60
Study 32022581 — intervention group
Group type: COMPARATOR
Intervention: Manual acupuncture (MA)
Number of subjects: 60
Study 32022581 — intervention group
Group type: COMPARATOR
Intervention: Electroacupuncture (EA) vs Manual acupuncture (MA)
Number of subjects: 60
Study 32022581 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) and Manual acupuncture (MA)
Number of subjects: 60
Study 36376738 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 600 mg every 4 weeks
Number of subjects: 51
Study 36376738 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks
Number of subjects: 51
Study 36376738 — intervention group
Group type: EXPERIMENTAL
Intervention: Spesolimab 600 mg every 4 weeks (sensitivity analysis)
Number of subjects: 51
Study 33043600 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 4 weeks
Number of subjects: 739
Study 33043600 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab 100 mg every 8 weeks
Number of subjects: 739
Study 33043600 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab (both regimens)
Number of subjects: 739
Study 33043600 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab
Number of subjects: 739
Study 32682482 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent ERCP with sphincterotomy
Number of subjects: 232
Study 32682482 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 232
Study 34296639 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural mobilization (straight leg raising and dorsiflexion with two‐ended slider), administered three times/week for six weeks
Number of subjects: 60
Study 34296639 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative physical therapy program only
Number of subjects: 60
Study 32506325 — intervention group
Group type: EXPERIMENTAL
Intervention: Online follow-up on the first, third, and fifth days after tooth extraction
Number of subjects: 0
Study 32506325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no follow-up)
Number of subjects: 0
Study 32506325 — intervention group
Group type: EXPERIMENTAL
Intervention: Online follow-up approval by senior doctors
Number of subjects: 0
Study 32506325 — intervention group
Group type: EXPERIMENTAL
Intervention: Online follow-up approval by young doctors
Number of subjects: 0
Study 34174507 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT)
Number of subjects: 76
Study 34058845 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress echocardiogram after 1 year
Number of subjects: 208
Study 34058845 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina assessment using Seattle Angina Questionnaire
Number of subjects: 208
Study 35477454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glycemic control
Number of subjects: 12042
Study 35477454 — intervention group
Group type: COMPARATOR
Intervention: Standard glycemic control
Number of subjects: 12042
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging lesions
Number of subjects: 1752
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 1752
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 1752
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission systolic blood pressure
Number of subjects: 1752
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline hematoma volume
Number of subjects: 1752
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral microbleeds
Number of subjects: 1752
Study 32687564 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukoaraiosis
Number of subjects: 1752
Study 34179697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance for 2 years
Number of subjects: 206
Study 34179697 — intervention group
Group type: COMPARATOR
Intervention: Observation after immunochemotherapy
Number of subjects: 206
Study 34179697 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab maintenance
Number of subjects: 206
Study 34179697 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 206
Study 32056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Skills for Life - adolescent version (SSL-A) over an 8-week period
Number of subjects: 61
Study 32056776 — intervention group
Group type: EXPERIMENTAL
Intervention: Super Skills for Life - adolescent version (SSL-A)
Number of subjects: 61